navicixizumab

bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor

Also Known As:

OMP-305B83

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Bispecific Antibodies: 968
        navicixizumab: 3
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Bispecific Antibodies: 968
        navicixizumab: 3
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Bispecific Antibodies: 968
        navicixizumab: 3

Experts

1.	Moore, Kathleen N: 2 articles (10/2022 - 01/2019)
2.	Stagg, Robert: 2 articles (10/2022 - 01/2019)
3.	Benjamin, Laura: 1 article (10/2022)
4.	Corr, Bradley R: 1 article (10/2022)
5.	Culm-Merdek, Kerry: 1 article (10/2022)
6.	Fu, Siqing: 1 article (10/2022)
7.	Hamilton, Erika Paige: 1 article (10/2022)
8.	Mockbee, Colleen: 1 article (10/2022)
9.	Naumann, R Wendel: 1 article (10/2022)
10.	Rosengarten, Rafael D: 1 article (10/2022)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2019 - "Conclusions Navicixizumab can be safely administered with manageable toxicities and these data showed preliminary signs of antitumor activity in multiple tumor types, but was most promising in ovarian cancer. " 01/01/2022 - "Combined navicixizumab and paclitaxel showed durable activity in patients with platinum-resistant ovarian cancer." 01/01/2022 - "Navicixizumab plus Paclitaxel Shows Clinical Benefit in Platinum-Resistant Ovarian Cancer." 10/01/2022 - "Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity." 10/01/2022 - "This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and delta-like ligand 4, against platinum-resistant ovarian cancer. "
2.	Neoplasms (Cancer) 01/01/2019 - "This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients. " 01/01/2019 - "Conclusions Navicixizumab can be safely administered with manageable toxicities and these data showed preliminary signs of antitumor activity in multiple tumor types, but was most promising in ovarian cancer. " 01/01/2019 - "A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors." 10/01/2022 - "An RNA-based diagnostic panel was retrospectively used to test the hypothesis that tumors with high angiogenesis or immune-suppressed tumor microenvironment (TME) subtypes (biomarker-positive) are more likely to respond to navicixizumab than those with immune-active/-desert TME subtypes (biomarker-negative). "
3.	Fallopian Tube Neoplasms 10/01/2022 - "Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer."

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Paclitaxel (Taxol)
3.	Platinum
4.	delta protein
5.	Biomarkers (Surrogate Marker)
6.	RNA (Ribonucleic Acid)
7.	Bevacizumab (Avastin)